A Robust, Durable, and Effective Treatment Combination for Advanced Cervical Cancer

The treatment combination of camrelizumab plus apatinib demonstrates robust and sustained efficacy in treating patients with advanced cervical cancer, according to a study published in Cancer Communications.

This analysis presented updated long-term results from the CLAP study. In this phase II trial, researchers enrolled 45 patients between January 21 and August 1, 2019. The population  received camrelizumab 200 mg intravenously every two weeks and apatinib 250 mg orally once daily in 4-week cycles for up to two years. The investigators noted that treatment was continued until disease progression, unacceptable toxicity, or withdrawal of consent.

The results showed that median duration of response (DOR) was 16.6 months, and 45% of patients achieved a DOR of ≥ 24 months. The 12-month progression-free survival (PFS) rate was 40.7% (95% confidence interval [CI], 25.2-55.6), with an 18-month PFS rate of 37.8% (95% CI, 22.7-52.8). The researchers observed that the median overall survival (OS) was 20.3 months (95% CI, 9.3-36.9), and the 24-month OS rate was 47.8% (95% CI, 31.7-62.3). Factors including age (over 50 years), programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 1 (versus [vs.] < 1), CPS ≥ 10 (vs. < 1), high tumor mutational burden, and PIK3CA mutations were associated with improved PFS (hazard ratio [HR] < 1) and longer OS (HR < 1).

“Long-term survival follow-up data demonstrated that camrelizumab plus apatinib has robust, sustained, and durable efficacy in patients with advanced cervical cancer who progress after first-line platinum-based chemotherapy. No new safety signals were noted with long-term treatment,” the researchers concluded.